Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endocrinology | 37 | 2023 | 139 | 13.760 |
Why?
|
| Diabetes Mellitus | 37 | 2025 | 848 | 9.260 |
Why?
|
| Standard of Care | 35 | 2023 | 129 | 3.830 |
Why?
|
| Reference Standards | 35 | 2023 | 239 | 3.820 |
Why?
|
| Societies, Medical | 36 | 2023 | 676 | 3.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2025 | 796 | 2.870 |
Why?
|
| Transition to Adult Care | 7 | 2025 | 119 | 1.890 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2023 | 1231 | 1.670 |
Why?
|
| Retinal Diseases | 2 | 2023 | 172 | 0.820 |
Why?
|
| Insulin | 5 | 2022 | 1200 | 0.730 |
Why?
|
| Humans | 59 | 2025 | 123180 | 0.650 |
Why?
|
| Prescription Drugs | 1 | 2020 | 52 | 0.640 |
Why?
|
| Hypoglycemic Agents | 7 | 2022 | 426 | 0.630 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 12 | 0.620 |
Why?
|
| Hyperglycemia | 1 | 2020 | 221 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 254 | 0.560 |
Why?
|
| Blood Glucose | 6 | 2022 | 1119 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 716 | 0.550 |
Why?
|
| Dyslipidemias | 1 | 2018 | 229 | 0.500 |
Why?
|
| Adolescent Development | 1 | 2013 | 26 | 0.430 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 1864 | 0.410 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 642 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 715 | 0.370 |
Why?
|
| Comorbidity | 4 | 2023 | 1497 | 0.340 |
Why?
|
| Adolescent | 17 | 2025 | 19111 | 0.340 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2021 | 154 | 0.320 |
Why?
|
| Physicians | 1 | 2015 | 583 | 0.310 |
Why?
|
| Clinical Competence | 1 | 2015 | 973 | 0.300 |
Why?
|
| Young Adult | 10 | 2025 | 8864 | 0.250 |
Why?
|
| Insulin Infusion Systems | 3 | 2020 | 61 | 0.240 |
Why?
|
| Child | 13 | 2024 | 24247 | 0.240 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2020 | 112 | 0.230 |
Why?
|
| Peer Group | 1 | 2024 | 116 | 0.220 |
Why?
|
| Mentors | 1 | 2024 | 145 | 0.210 |
Why?
|
| Liraglutide | 1 | 2022 | 14 | 0.200 |
Why?
|
| Quality Improvement | 3 | 2023 | 626 | 0.200 |
Why?
|
| Hospitals | 2 | 2023 | 393 | 0.200 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 68 | 0.200 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 3375 | 0.190 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 65 | 0.190 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2023 | 128 | 0.190 |
Why?
|
| Health Personnel | 1 | 2024 | 493 | 0.170 |
Why?
|
| Adult | 12 | 2025 | 29032 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2022 | 424 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 196 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2021 | 220 | 0.150 |
Why?
|
| Passeriformes | 1 | 2008 | 2 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2018 | 44 | 0.150 |
Why?
|
| Spatial Behavior | 1 | 2008 | 15 | 0.150 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 52 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 271 | 0.140 |
Why?
|
| Pregnancy | 4 | 2023 | 7146 | 0.140 |
Why?
|
| Health Education | 1 | 2018 | 225 | 0.140 |
Why?
|
| Female | 13 | 2024 | 65562 | 0.140 |
Why?
|
| Behavior, Animal | 1 | 2008 | 476 | 0.120 |
Why?
|
| Pediatrics | 2 | 2014 | 1142 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1139 | 0.120 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2014 | 34 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 94 | 0.110 |
Why?
|
| Psychology, Adolescent | 1 | 2013 | 33 | 0.110 |
Why?
|
| Obesity | 2 | 2023 | 2230 | 0.110 |
Why?
|
| Puberty | 1 | 2013 | 94 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2013 | 121 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1739 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 1286 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 171 | 0.100 |
Why?
|
| United States | 4 | 2021 | 10660 | 0.100 |
Why?
|
| Social Support | 1 | 2013 | 345 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2013 | 308 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 451 | 0.090 |
Why?
|
| Self Care | 2 | 2024 | 213 | 0.080 |
Why?
|
| Male | 8 | 2024 | 60173 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1258 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2013 | 752 | 0.070 |
Why?
|
| Aged | 2 | 2023 | 19108 | 0.070 |
Why?
|
| Learning | 2 | 2020 | 361 | 0.060 |
Why?
|
| Registries | 2 | 2021 | 1394 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 2799 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 1924 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 132 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2018 | 12142 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3670 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2021 | 25 | 0.050 |
Why?
|
| Parity | 1 | 2020 | 78 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 2943 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 40 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2021 | 13904 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 293 | 0.040 |
Why?
|
| Health Behavior | 1 | 2023 | 382 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 148 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 608 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2023 | 549 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 581 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2020 | 348 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 861 | 0.040 |
Why?
|
| Orientation | 1 | 2008 | 49 | 0.040 |
Why?
|
| Cues | 1 | 2008 | 89 | 0.040 |
Why?
|
| Space Perception | 1 | 2008 | 61 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 864 | 0.040 |
Why?
|
| Triglycerides | 1 | 2020 | 561 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2020 | 324 | 0.040 |
Why?
|
| Glucose | 1 | 2021 | 875 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 711 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10031 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 557 | 0.030 |
Why?
|
| Counseling | 1 | 2016 | 218 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 718 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2028 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2397 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1389 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2113 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 828 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 3327 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4512 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 622 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3565 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6221 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8115 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 12371 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 33798 | 0.010 |
Why?
|